Skip to content
HowShorted

Adamas Pharmaceuticals Inc short interest in 2019

In 2019, Adamas Pharmaceuticals Inc's disclosed short interest ran from 24.74% of shares outstanding on 15 Jan 2019 to 8.55% on 31 Dec 2019, a change of -16.19 percentage points. The year's high was 24.74% on 15 Jan 2019 and its low 6.63% on 13 Dec 2019, averaging 16.35% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 28.68 days on 30 Apr 2019. Full history: Adamas Pharmaceuticals Inc.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021

Aggregate net short position time series for Adamas Pharmaceuticals Inc in 2019

2019 in figures

Start of year
24.74% (15 Jan 2019)
End of year
8.55% (31 Dec 2019)
Change
-16.19 pp
High
24.74% (15 Jan 2019)
Low
6.63% (13 Dec 2019)
Average
16.35%
Highest days to cover
28.68 (30 Apr 2019)
SEC filings marked
9

Every report in 2019

Adamas Pharmaceuticals Inc short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 201924.74%13.56results (8-K)
31 Jan 201923.46%16.58
15 Feb 201919.69%10.82
28 Feb 201921.03%16.31
15 Mar 201924.60%4.9910-K filed, results (8-K)
29 Mar 201924.37%20.87
15 Apr 201922.99%12.08
30 Apr 201922.73%28.68
15 May 201920.89%13.3110-Q filed, results (8-K)
31 May 201919.30%8.82
14 Jun 201918.99%23.38
28 Jun 201916.56%11.49
15 Jul 201916.65%18.66
31 Jul 201913.74%13.33
15 Aug 201913.52%8.5410-Q filed, results (8-K)
30 Aug 201910.24%8.18
13 Sep 20198.69%5.62
30 Sep 20197.23%2.01
15 Oct 201911.91%3.70
31 Oct 201914.04%12.70
15 Nov 201912.67%8.9510-Q filed, results (8-K)
29 Nov 20199.08%7.29
13 Dec 20196.63%4.16
31 Dec 20198.55%1.80

See also: Adamas Pharmaceuticals Inc's full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.